Appointment of Non-Executive Director

Bioventix plc

("Bioventix" or the "Company")

Appointment of Non-Executive Director

Bioventix PLC (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is delighted to announce the appointment of Chris Yates as independent Non-Executive Director, with effect from 1st March 2026.

Chris brings extensive board‑level and sector expertise, underpinned by over 20 years' experience operating within publicly listed company environments. Over the past decade, Chris has led the development and growth of Abingdon Health plc. Chris co-founded the business in 2008, initially serving as Non-Executive Director and then in 2015 becoming Chief Executive Officer until 2025 when he was appointed President of Abingdon Health USA and Group Chief Commercial Officer. Chris also serves as a Non-Executive Director and Chairman of the Audit Committee of AIM-listed Genedrive plc. Earlier in his career, Chris was CFO of AIM-listed companies Immunodiagnostic Systems Holdings PLC and Cozart plc.

Chris is a Chartered Accountant and has a degree in economics from the University of Cambridge.

For further information please contact:

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

Further disclosures pursuant to Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies:

Chris Henry Francis Yates

The following information regarding the appointment of Chris Yates, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

Chris Yates does not hold any shares in Bioventix.

There are no further disclosures to be made under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.